• Home
  • Adagrasib 200mg
  • Adagrasib 200mg

Adagrasib 200mg

52140

Adagrasib is used for adults with non-small cell lung cancer that has a KRAS G12C mutation, has spread or cannot be removed by surgery, and has already been treated with another systemic cancer treatment.

It is also used with cetuximab for some adults with colorectal cancer that has a KRAS G12C mutation after earlier standard treatments have stopped working.

Usual adult dose range: 400mg to 600mg twice daily; the usual starting dose for approved cancer uses is 600mg twice daily, with lower doses used if needed for side effects.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.